Search For Lab Tests Here

The Preventive Health & Cancer Screening Support - Comprehensive Male Lab Panel includes 22 tests and 125 biomarkers to support physician-guided review of preventive wellness and selected cancer marker support labs for men. It includes CBC, CMP, FIT/InSure®, PSA free and total, AFP/AFP-L3, CEA, CA 19-9, hepatitis, liver, kidney, thyroid, iron, inflammation, urinalysis, vitamin D, lipids, glucose, cystatin C, and immune protein labs.

The Preventive Health & Cancer Marker Lab Panel - Advanced Male includes 19 tests and 114 biomarkers to support physician-guided review of preventive wellness and selected cancer marker patterns. It includes CBC, CMP, FIT/InSure®, PSA free and total, AFP/AFP-L3, CEA, CA 19-9, liver, kidney, thyroid, iron, inflammation, urinalysis, vitamin D, lipids, glucose, cystatin C, urine albumin, GGT, bilirubin, ferritin, and iron/TIBC.

The Preventive Health & Cancer Marker Lab Panel — Comprehensive Female includes 27 tests and 137 biomarkers to support physician-guided review of preventive wellness and selected cancer marker support labs for women. It includes CBC, CMP, FIT/InSure®, liver, kidney, thyroid, iron, inflammation, hepatitis, urinalysis, vitamin D, lipids, glucose, immune protein markers, and tumor marker support labs such as CA 125, CA 15-3, CA 27.29, CA 19-9, CEA, and AFP/AFP-L3.

The Preventive Health & Cancer Marker Lab Panel - Advanced Female includes 23 tests and 116 biomarkers to support physician-guided review of preventive wellness and selected cancer marker patterns. It includes CBC, CMP, FIT/InSure®, CA 125, CA 15-3, CA 27.29, CA 19-9, CEA, AFP/AFP-L3, kidney, liver, thyroid, iron, inflammation, urinalysis, vitamin D, lipids, glucose, cystatin C, urine albumin, GGT, bilirubin, ferritin, and Free T3/T4.

The CA 15-3 Test measures cancer antigen 15-3 levels in blood, often used to monitor breast cancer treatment and progression. Elevated levels may suggest advanced breast cancer, metastasis, or recurrence, while non-cancer conditions can also affect results. Doctors order this test alongside imaging and other labs to track therapy response or detect changes in disease status. Results help guide ongoing management of breast cancer and patient care.

The CA 125 Test measures the level of cancer antigen 125 in blood, a protein often elevated in ovarian cancer and some other conditions. While not used alone for diagnosis, it helps monitor treatment effectiveness, detect recurrence, or assess disease progression. Elevated CA 125 may also be seen in endometriosis, fibroids, or pelvic inflammation. Doctors use this test to support cancer management and track overall reproductive and abdominal health.

The CA 19-9 Test measures levels of carbohydrate antigen 19-9 in blood, a tumor marker often elevated in pancreatic cancer and sometimes in bile duct, colorectal, or liver cancers. While not used alone for diagnosis, it helps monitor treatment, track disease progression, and detect recurrence. Elevated CA 19-9 may also occur in noncancerous conditions. Doctors use this test to support cancer management and guide therapy decisions.

 The CA-2 Cancer Screening - Women panel is a specialized diagnostic tool designed for the early detection and ongoing monitoring of various cancers specifically in women. It expands upon basic cancer screening by including additional markers that provide a wider range of detection and insight into different types of cancers. This panel is particularly valuable for women who are at increased risk due to genetic predispositions, family history, or environmental factors. It helps in the early identification of cancer, potentially improving the effectiveness of treatments and increasing the chances of successful outcomes.

The Vascular Endothelial Growth Factor (VEGF) Test measures VEGF levels in blood to assess abnormal blood vessel growth and vascular health. Elevated VEGF may be associated with cancers, macular degeneration, diabetic retinopathy, or inflammatory disorders. Doctors use this test to evaluate angiogenesis activity, investigate unexplained vision changes or tumor growth, and guide treatment strategies for cancer or vascular-related conditions.

The Alpha-Fetoprotein (AFP) and AFP-L3 Test measures total AFP and the AFP-L3 fraction, which is more specific for liver cancer risk. Elevated AFP may indicate liver disease, germ cell tumors, or hepatitis, while AFP-L3 is strongly associated with hepatocellular carcinoma (HCC). Doctors order this test to assess liver function, screen high-risk patients, and monitor cancer treatment. Results provide critical insight into liver health and cancer detection.

 The CA-1 Cancer Screening - Women panel is specifically designed as an initial screening tool for the early detection of various cancers that commonly affect women. This panel combines several tumor markers and protein measurements, each carefully selected for their relevance in detecting specific cancer types. The panel is an important resource for those who are at increased risk of cancer, either due to family history, genetic predisposition, or other risk factors. By measuring specific biomarkers, this panel helps in identifying cancer at an early stage, where treatment can be more effective and less invasive.

The Fecal Globin by Immunochemistry Test detects hidden (occult) blood in stool using antibodies that identify human globin protein. This test helps screen for colorectal cancer, polyps, ulcers, and gastrointestinal bleeding. Doctors order it when patients have anemia, abdominal pain, or changes in bowel habits. Results provide early detection of digestive tract bleeding, guiding further evaluation with colonoscopy or other diagnostic procedures.

The Hepatitis B Surface Antigen (HBsAg) Test with Reflex to Confirmation screens for hepatitis B surface antigen in blood and, if reactive, automatically performs confirmatory testing. A reactive confirmed result indicates an active hepatitis B infection, while a non-reactive result shows no infection. Doctors use this test to diagnose acute or chronic hepatitis B, investigate abnormal liver tests, and guide treatment, monitoring, and infection control decisions.